Scotiabank Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock

Key Points

• Scotiabank raised Pfizer’s price target from $33 to $35 and maintained a “sector outperform” rating, implying 13.66% upside from the share price cited in the report.
• Analyst sentiment overall remained cautious: Pfizer had a consensus “Hold” rating and an average price target of $29.12, with five Buy, 13 Hold and two Sell ratings.
• Pfizer reported quarterly earnings of $0.87 per share and revenue of $16.58 billion, beating analyst estimates for both; revenue was down 0.4% year over year.

Pfizer (NYSE:PFE - Get Free Report) had its price target boosted by stock analysts at Scotiabank from $33.00 to $35.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a "sector outperform" rating on the biopharmaceutical company's stock. Scotiabank's price objective suggests a potential upside of 13.66% from the stock's current price.

Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 9th. HSBC lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, September 10th. Citigroup increased their price objective on Pfizer from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Wednesday. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Finally, Royal Bank Of Canada upped their target price on shares of Pfizer from $25.00 to $28.00 and gave the stock a "sector perform" rating in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $29.12.

Pfizer Stock Up 2.6%

Shares of NYSE:PFE traded up $0.79 during trading on Wednesday, reaching $30.79. 50,321,531 shares of the stock were exchanged, compared to its average volume of 39,819,855. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.06. The stock has a fifty day moving average of $28.64 and a two-hundred day moving average of $26.84. The firm has a market cap of $175.52 billion, a price-to-earnings ratio of 40.52, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the company posted $0.87 earnings per share. The business's revenue was down .4% on a year-over-year basis. Research analysts anticipate that Pfizer will post 2.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Large investors have recently modified their holdings of the business. Bank of America Corp DE acquired a new stake in Pfizer during the second quarter valued at approximately $1,049,602,000. BlackRock Inc. lifted its stake in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. Nykredit A S acquired a new position in Pfizer in the 2nd quarter valued at approximately $205,774,000. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company's stock worth $286,609,000 after acquiring an additional 5,829,204 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after buying an additional 5,501,032 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised 2026 guidance to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Growth is increasingly coming from beyond COVID: non-COVID products grew 7% operationally, while launched and acquired products grew 32%. Eliquis, Padcev and other newer medicines helped support results, strengthening the case that Pfizer’s portfolio can offset pandemic-product weakness. Article: Non-COVID Portfolio Steps Up
• Positive Sentiment: Management is also pursuing growth in obesity medicines, with CEO Albert Bourla saying Pfizer aims to bring its past commercial experience to the weight-loss market. That opportunity could add longer-term upside, though it depends on pipeline and development progress. Article: Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. The appointment provides continuity, but the announcement itself offers limited immediate evidence of a change in financial performance. Article: Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Quarterly revenue was nearly flat year over year as Comirnaty and Paxlovid sales declined sharply. This highlights the continuing challenge of replacing pandemic-era revenue and leaves Pfizer reliant on sustained growth from newer products. Article: Pfizer Q3 Revenue and Product Growth
• Negative Sentiment: Analyst views remain restrained: RBC raised its target to $28 but kept a “sector perform” rating, and J.P. Morgan assigned a “Hold.” RBC’s target is below the cited $30.75 share price, signaling limited upside in its assessment. Article: RBC Raises Pfizer Price Target

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.